Jan 02, 2019

GNS Co-Founder and CEO Colin Hill Discusses how AI will Power the Future of in silico Clinical Trials

GNS Co-Founder and CEO Colin Hill sat down with Outsourcing Pharma‘s Melissa Fassbender to discuss how in silico are making personalized medicine a reality. The interview covered how technology is driving pharma efforts to transition from resource-intensive trials to more flexible and fast paced trials with the help of AI. Read the full interview here.